News & Events

Disc Medicine Announces Completion of Merger with Gemini Therapeutics

The combined company will operate as Disc Medicine and will trade on the Nasdaq Global Market under the ticker symbol “IRON” Approximately $175 million of cash and cash equivalents to provide operating runway into 2025 WATERTOWN, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) — Disc Medicine, Inc.

More News

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic...


read more

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from...


read more

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more